Search Results
Your search for ,wAS matches 28044 pages
Showing 6901 - 6950Intracranial Efficacy of Lorlatinib vs Crizotinib in ALK-Positive Advanced NSCLC
In a post hoc analysis from the phase III CROWN trial reported in the Journal of Clinical Oncology, Benjamin J. Solomon, MBBS, PhD, and colleagues found that progression-free survival and the risk of central nervous system (CNS) progression were improved with lorlatinib vs crizotinib in previously...
Real-World Uptake of FGFR-Alteration Testing and Gene-Targeted Therapy for Patients With Urothelial Cancer
In a study reported in a research letter in JAMA Oncology, Nimgaonkar et al found that less than half of patients with urothelial cancer who had received first-line platinum-based therapy underwent testing for FGFR alterations and that less than half of patients with susceptible alterations...
Metformin vs Placebo in Patients With High-Risk Operable Breast Cancer Receiving Standard Treatment
As reported in JAMA by Pamela J. Goodwin, MD, MSc, FRCPC, FASCO, the phase III MA.32 trial showed no invasive disease–free survival benefit with metformin vs placebo in patients without diabetes receiving standard therapy for high-risk nonmetastatic breast cancer. Study Details In the double-blind ...
Allogeneic CAR T-Cell Therapy for Relapsed or Refractory T-Cell Lymphoma
Patients with relapsed or refractory T-cell lymphoma have limited treatment options. Chimeric antigen receptor (CAR) T-cell therapy has been challenging in these patients because of the state of their T cells. CTX130 is an allogeneic CAR T-cell therapy targeting CD70 on cancerous T cells, offering...
Ponatinib Plus Blinatumomab for Patients With Philadelphia Chromosome–Positive ALL
The tyrosine kinase inhibitor ponatinib and monoclonal antibody blinatumomab—which targets CD19 on leukemia cells—are highly effective as monotherapies for patients with Philadelphia chromosome–positive (Ph+) acute lymphoblastic leukemia (ALL). The combination of the two therapies may provide an...
MajesTEC-1: Bispecific Antibody Teclistamab for Relapsed or Refractory Multiple Myeloma
In the phase I/II MajesTEC-1 trial presented at the 2022 ASCO Annual Meeting (Abstract 8007) and simultaneously published in The New England Journal of Medicine, Philippe Moreau, MD, and colleagues found that the bispecific antibody teclistamab produced responses in nearly two-thirds of patients...
Personalized ctDNA Testing and Late Recurrence in High-Risk HR-Positive, HER2-Negative Breast Cancer
In a study presented at the 2022 ASCO Annual Meeting (Abstract 103) and simultaneously reported in the Journal of Clinical Oncology, Lipsyc-Sharf et al found that personalized circulating tumor DNA (ctDNA) testing was successful in detecting measurable residual disease (MRD) prior to late clinical...
Differences in Germline Variant Spectrum Between Black and White Men With Prostate Cancer
In a study presented at the 2022 ASCO Annual Meeting (Abstract 10502) and simultaneously published in JCO Precision Oncology, Veda N. Giri, MD, and colleagues found that Black men with prostate cancer exhibited a lower frequency and narrower spectrum of germline pathogenic or likely pathogenic...
ASCO’s CancerLinQ® and Atropos Health Collaborate to Harness Real-World Data to Provide Point-of-Care Informatics Consult to Oncologists
ASCO’s CancerLinQ® and Atropos Health announced a new collaboration that will provide oncology clinicians with the latest real-world evidence available to help inform personalized care and treatment of an individual patient. Atropos Health and CancerLinQ will work together to provide a “digital...
Ralph Lauren Corporate Foundation Announces $25 Million Commitment to Five U.S. Cancer Centers to Help Reduce Disparities in Cancer Care in Underserved Communities
The Ralph Lauren Corporate Foundation recently announced it will provide $25 million in new grant funding to expand or establish five Ralph Lauren cancer centers, aimed at reducing disparities in cancer care and access across underserved communities in the United States. The funding will benefit...
The Mark Foundation for Cancer Research Appoints Ryan Schoenfeld, PhD, as Chief Executive Officer
The Mark Foundation for Cancer Research, which actively partners with scientists, research institutions, and philanthropic organizations around the world to accelerate research in the prevention, diagnosis, and treatment of cancer, recently announced that Ryan Schoenfeld, PhD, has been appointed...
Cleveland Clinic Announces New Appointments to Oncology Staff
The Cleveland Clinic-Taussig Cancer Center recently announced two new appointments and updates to the Center’s staff and faculty. Sophia Balderman, MD, has joined the leukemia group at Taussig Cancer Institute. Prior to her new role, Dr. Balderman was Assistant Professor in the Department of...
Robotic Surgery Improves Perioperative Outcomes vs Open Radical Cystectomy in Bladder Cancer Trial
Patients who underwent robotic-assisted radical cystectomy with intracorporeal diversion spent fewer days in the hospital and experienced fewer complications compared with those who underwent open radical cystectomy, according to data presented at the 2022 American Urological Association (AUA)...
Researcher Xiao-Jing Wang, MD, PhD, Joins UC Davis Cancer Center’s Leadership Team
Xiao-Jing Wang, MD, PhD, assumed the role of Chief Science Officer and Associate Director for Basic Science for the UC Davis Comprehensive Cancer Center in Davis, California. She is also Associate Director for Basic Science. Dr. Wang comes to UC Davis from the University of Colorado Anschutz...
Emily Whitehead, First Pediatric Patient to Receive CAR T-Cell Therapy, Celebrates Remission 10 Years Later
Tom and Kari Whitehead came to Children’s Hospital of Philadelphia (CHOP) 10 years ago looking for a miracle. Their 6-year-old daughter, Emily, had relapsed in her battle with acute lymphoblastic leukemia (ALL), after many months of unsuccessful chemotherapy and a disease that had progressed so...
Expert Point of View: Mafalda Oliveira, MD, PhD
The invited discussant of the TUXEDO-1 trial1 was Mafalda Oliveira, MD, PhD, of Vall d’Hebron University Hospital and Vall d’Hebron Institute of Oncology, Barcelona. Dr. Oliveira noted that 40% of the 15 patients in TUXEDO-1 had symptomatic disease, and 60% had central nervous system metastases...
Annual Meeting of the Moroccan Cancer Society: An Opportunity for Young Cancer Researchers to Evolve
The Moroccan Cancer Society (MCS; Société Marocaine de Cancérologie/https://smc.ma) was created in 1992 by a group of Moroccan medical and radiation oncologists, surgeons, and pathologists who had led the field in the 1980s. To date, this scientific society has more than 350 members practicing in...
T-DXd Shows Efficacy Against Active Brain Metastases in HER2-Positive Breast Cancer
In the single-center phase II TUXEDO-1 trial of patients with advanced HER2-positive breast cancer, fam-trastuzumab-deruxtecan-nxki (T-DXd) showed efficacy in patients with active brain metastases, yielding intracranial responses in 73.3% of the population and a median progression-free survival of...
Use of T-DXd in Previously Treated Patients With Advanced HER2-Positive Breast Cancer
On May 4, 2022, fam-trastuzumab deruxtecan-nxki (T-DXd) was granted regular approval for patients with unresectable or metastatic HER2-positive breast cancer who have received a prior anti-HER2–based regimen in the metastatic setting or in the neoadjuvant or adjuvant setting and have developed...
Traditional Chinese Medicine Herbal Formula Ma Zi Ren Wan for Constipation
The ASCO Post’s Integrative Oncology series is intended to facilitate the availability of evidence-based information on integrative and complementary therapies sometimes used by patients with cancer. In this installment, Eugenie Spiguel, MSN, ANP-BS, and Jyothirmai Gubili, MS, focus on Ma Zi Ren...
How Social Media Is Fueling an Epidemic of Misinformation and Disinformation—and Distrust in Science
The COVID-19 pandemic and the confluence of events that followed—including the rapid development of vaccines, the mixed messaging on mitigation efforts to prevent coronavirus infection, and the growing political polarization—helped spark public mistrust and skepticism toward science. This mistrust...
NCCN Honors Oncology Leaders Promoting Progress in Cancer Care
The National Comprehensive Cancer Network® (NCCN®) recently announced the recipients of 2022 awards for both internal and external champions advancing NCCN’s mission and helping all people with cancer to live better lives. The annual awards include the Rodger Winn Award for expert judgment and...
Cemiplimab-rwlc Following Platinum-Based Chemotherapy in Recurrent or Metastatic Cervical Cancer: Clinical Implications
It is estimated that globally, more than 600,000 women per year are diagnosed with cervical cancer, and more than 300,000 die annually of the disease.1 Many women continue to be diagnosed with cervical cancer at an advanced stage, with a high risk of recurrence. To date, the most effective...
Cemiplimab-rwlc Improves Overall Survival vs Chemotherapy in Recurrent Cervical Cancer After First-Line Platinum-Based Chemotherapy
As reported in The New England Journal of Medicine by Krishnansu S. Tewari, MD, of the Division of Gynecologic Oncology, University of California, Irvine, and colleagues, the phase III EMPOWER-Cervical1/GOG-3016/ENGOT-cx9 trial has shown improved overall survival with cemiplimab-rwlc vs...
Expert Point of View: Mafalda Oliveira, MD, PhD
The invited discussant of the BEGONIA trial,1 Mafalda Oliveira, MD, PhD, of Vall d’Hebron University Hospital and Vall d’Hebron Institute of Oncology, Barcelona, called the activity of the combination of durvalumab and datopotamab deruxtecan (Dato-DXd) “notable,” with a 74% response rate overall,...
BEGONIA Trial Reports Activity With Datopotamab Deruxtecan Plus Durvalumab in Triple-Negative Breast Cancer
Preliminary results of the basket BEGONIA trial showed that the antibody-drug conjugate datopotamab deruxtecan (Dato-DXd), paired with the immune checkpoint inhibitor durvalumab, has strong activity in advanced or metastatic triple-negative breast cancer among patients not biomarker-selected for...
DESTINY-Breast03: Should Trastuzumab Deruxtecan Be the Preferred Second-Line Regimen in HER2-Positive Metastatic Breast Cancer?
Since the introduction of trastuzumab in the late 1990s, overall survival for patients with HER2-positive metastatic breast cancer has substantially improved. Median overall survival in the pivotal first-line trial was only 20.3 months in the chemotherapy arm, and 25.1 months in the...
MONALEESA-3: Ribociclib Plus Fulvestrant Improves Overall Survival Over Fulvestrant Alone in the First-Line Setting
In an updated analysis of the phase III MONALEESA-3 trial, which included postmenopausal patients with hormone receptor–positive, HER2-negative advanced or metastatic breast cancer, first-line treatment with ribociclib plus fulvestrant added nearly 16 months of overall survival time vs fulvestrant...
T-DXd Improves Progression-Free Survival vs T-DM1 in Metastatic HER2-Positive Breast Cancer
As reported in The New England Journal of Medicine by Javier Cortés, MD, PhD, of the International Breast Cancer Center, Barcelona, and colleagues, the phase III DESTINY-Breast03 trial has shown significantly prolonged progression-free survival with fam-trastuzumab deruxtecan-nxki (T-DXd) vs...
Momelotinib for Symptomatic and Anemic Patients With Myelofibrosis
Once-daily treatment with the oral JAK1/2 and ACVR1/ALK2 inhibitor momelotinib significantly improved outcomes of patients treated for myelofibrosis. Ruben Mesa, MD, FACP, and colleagues presented results of the MOMENTUM phase III randomized study, which evaluated momelotinib vs danazol in...
Ciltacabtagene Autoleucel in Relapsed or Refractory Multiple Myeloma: 2-Year Follow-up of CARTITUDE-1 Trial
In an analysis presented at the 2022 ASCO Annual Meeting (Abstract 8028) and simultaneously reported in the Journal of Clinical Oncology, Thomas Martin, MD, and colleagues provided data from the 2-year follow-up of the pivotal CARTITUDE-1 trial of the anti–B-cell maturation agent (BCMA) chimeric...
Incidence of Major Adverse Cardiac Events in Patients Receiving Immune Checkpoint Inhibitors
In a study presented at the 2022 ASCO Annual Meeting (Abstract 2508) and simultaneously reported in the Journal of Clinical Oncology, Naqash et al identified the incidence of major adverse cardiac events among patients receiving immune checkpoint inhibitors for cancer as captured in the serious...
Brexucabtagene Autoleucel in Relapsed or Refractory Mantle Cell Lymphoma: 3-Year Follow-up of ZUMA-2 Trial
In an analysis presented at the 2022 ASCO Annual Meeting (Abstract 7518) and simultaneously reported in the Journal of Clinical Oncology, Michael Wang, MD, and colleagues provided data from the 3-year follow-up of the pivotal ZUMA-2 trial of the chimeric antigen receptor (CAR) T-cell therapy...
Nabil F. Saba, MD, on Head and Neck Squamous Cell Carcinoma: Phase II Findings on Pembrolizumab and Cabozantinib
Nabil F. Saba, MD, of Winship Cancer Institute of Emory University, discusses new data from a trial of pembrolizumab and cabozantinib in patients with recurrent metastatic head and neck squamous cell carcinoma. The study met its primary endpoint of overall response rate. The regimen was well...
Neal D. Shore, MD, on Germline Genetic Testing and Its Impact on Prostate Cancer Clinical Decision-Making
Neal D. Shore, MD, of the Carolina Urologic Research Center, discusses his study findings, showing that germline genetic testing influenced care for patients with prostate cancer. Men whose genetic test was positive for a pathogenic germline variant received more recommendations for changes to...
Sumanta K. Pal, MD, on Urothelial Carcinoma: New Results on Cabozantinib Plus Atezolizumab
Sumanta K. Pal, MD, of City of Hope National Medical Center, discusses findings from the COSMIC-021 study, which showed that cabozantinib plus atezolizumab demonstrated encouraging clinical activity with manageable toxicity in patients with inoperable locally advanced or metastatic urothelial...
Capecitabine Plus Temozolomide vs Temozolomide Alone in Advanced Pancreatic Neuroendocrine Tumors
In the updated final analysis of the phase II ECOG-ACRIN E2211 trial, patients with advanced pancreatic neuroendocrine tumors experienced a significant improvement in progression-free survival with capecitabine plus temozolomide over temozolomide alone.1 Although the 5-month difference in overall...
FLT3 Inhibitor Crenolanib in Combination With Chemotherapy for Newly Diagnosed Patients With FLT3-Mutant AML
Eunice Wang, MD, Chief of Leukemia at Roswell Park Comprehensive Cancer Center, and colleagues presented the long-term results of a phase II clinical trial combining crenolanib, a second-generation FLT3 inhibitor, with standard intensive chemotherapy for the treatment of adults with newly diagnosed ...
mFOLFOXIRI/Panitumumab vs mFOLFOX/Panitumumab for the Initial Treatment of RAS and BRAF Wild-Type Metastatic Colorectal Cancer
In an Italian phase III trial (TRIPLETE) presented at the 2022 ASCO Annual Meeting (Abstract LBA3505) and simultaneously published in the Journal of Clinical Oncology, Rossini et al found that mFOLFOXIRI (modified fluorouracil, leucovorin, oxaliplatin, and irinotecan) plus panitumumab did not...
Ramucirumab/Pembrolizumab vs Standard of Care in Patients With Advanced NSCLC Previously Treated With Immune Checkpoint Inhibitors
In the phase II Lung-MAP substudy S1800A presented at the 2022 ASCO Annual Meeting (Abstract 9004) and simultaneously reported in the Journal of Clinical Oncology, Karen L. Reckamp, MD, and colleagues found that the combination of ramucirumab and pembrolizumab improved overall survival vs...
ATHENA-MONO Trial: Rucaparib Maintenance in Newly Diagnosed Patients With Advanced Ovarian Cancer
As presented at the 2022 ASCO Annual Meeting (Abstract LBA5500) and simultaneously reported in the Journal of Clinical Oncology by Bradley J. Monk, MD, and colleagues, the phase III ATHENA-MONO trial found that maintenance rucaparib significantly improved progression-free survival vs placebo among...
Patient-Facing Screening Tool Could Increase Detection of Individuals With Lynch Syndrome
Nearly 1 million people in the United States are affected by Lynch syndrome, a hereditary cancer condition with markedly elevated risk of gastrointestinal, endometrial, and other cancers. Most of them, however, are unaware of it, or find out only after they have developed cancer. A screening...
Immunotherapy Combination in Newly Diagnosed Glioblastoma
A novel combination of two experimental cancer immunotherapy agents along with an immune checkpoint blocker elicited robust immune responses in patients with newly diagnosed glioblastoma brain tumors, according to a presentation of interim, 2-year follow-up clinical trial data given by David...
Three-Arm First-Line Chemoimmunotherapy Study in Patients With Metastatic Pancreatic Cancer
Combinations of chemotherapy and immunotherapy showed activity in patients with metastatic pancreatic cancer, according to findings from a national, randomized clinical trial led and sponsored by the Parker Institute for Cancer Immunotherapy. The results of the small trial were presented by Padrón...
Study Finds Genetic Mutations Differ Across Younger and Older Patients With Breast Cancer
Women younger than age 40 with advanced breast cancer often experience more aggressive disease and worse prognoses than their older counterparts. Knowing which types of genetic mutations these patients tend to have may inform treatment strategies and improve outcomes. In a recent study, researchers ...
Did the ACA’S Medicaid Expansion Affect Cancer Clinical Trial Enrollment?
Researchers from the SWOG Cancer Research Network, a clinical trials group funded by the National Cancer Institute (NCI), found that the Affordable Care Act’s (ACA) expansion of Medicaid insurance in 2014 was followed by a significant increase in the proportion of patients enrolling in SWOG trials...
Biomarker Guidance May Allow Patients Aged 55 or Older With Low-Grade Luminal A–Type Breast Cancer to Avoid Radiation Therapy
Based on guidance from biomarker screening, patients with low-grade luminal A–type breast cancer aged 55 and older may need endocrine therapy alone following breast-conserving surgery and may be able to avoid radiation therapy entirely, according to new research findings presented by Timothy Joseph ...
Neoadjuvant Immunotherapy May Improve Survival for Patients With Soft-Tissue Sarcoma
In a phase II clinical trial, immune checkpoint blockade before surgery was associated with favorable responses and outcomes in undifferentiated pleomorphic sarcoma (UPS) and recurrent dedifferentiated liposarcoma (DDLPS), Keung et al reported at the 2022 ASCO Annual Meeting (Abstract LBA11501)....
Researchers Examine Racial Differences in Treatment and Outcomes of First-Line Therapies for Kidney Cancer
Black and White patients treated with similar first-line therapies for advanced kidney cancer experienced similar outcomes, but different response rates, according to research from Fox Chase Cancer Center presented by Daniel Geynisman, MD, at the 2022 ASCO Annual Meeting (Abstract 4548). “This was...
Study Examines Ancestry-Specific Genetic Risk for Triple-Negative Breast Cancer
Although women of African descent experience a higher incidence and mortality from triple-negative breast cancer than women of other races or ethnicities, research findings presented by Hall et al at the 2022 ASCO Annual Meeting showed that the magnitude of gene-specific risks of triple-negative...
